Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA), has reached a milestone with the commencement of its Single Ascending Dose (SAD) study for ISLA-101. This well-known drug candidate, repurposed for the prevention and treatment of dengue and other mosquito-borne diseases, represents a major advance in the field. The SAD study, conducted at Scientia Clinical Research’s facilities in Sydney, Australia, by Contract Research Organisation, Beyond Drug Development, is a critical step towards realizing the potential of ISLA-101.

Details of the ISLA-101 Single Ascending Dose Study

The study involves a dose escalation method where three cohorts of healthy subjects will receive escalating doses of ISLA-101. The primary goal is to ensure that administered doses achieve blood concentrations that are predicted to be effective against the dengue virus. Data readouts from the study are anticipated in early 2024, providing vital insights for the planned Phase 2a PEACH clinical trial.

Island Pharmaceuticals’ Focus on Antiviral Therapeutics

Island Pharmaceuticals, a drug repurposing company, has concentrated its efforts on antiviral therapeutics, addressing areas of unmet need in infectious diseases. The company’s lead asset, ISLA-101, boasts a well-established safety profile and is being repurposed to target dengue fever and other mosquito-borne diseases.

Leadership Comments on the Study Progress

Dr. David Foster, CEO of Island Pharmaceuticals, expressed his enthusiasm for the start of the study, emphasizing its importance for the upcoming PEACH clinical trial. The study marks a significant stride in the journey toward making ISLA-101 an approved treatment for dengue fever and other related diseases.

  Dengue, Dengue fever, Dr. David Foster, ISLA-101, Island Pharmaceuticals, Scientia Clinical Research